$CARM
Carisma Therapeutics Inc

2018 Q1 Form 10-K Financial Statement

#000148500318000034 Filed on April 02, 2018

View on sec.gov

Income Statement

Concept 2018 Q1 2017 Q4 2017
Revenue $0.00 $0.00 $0.00
YoY Change -100.0% -100.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.950M $1.990M $8.070M
YoY Change -11.76% -27.64% -45.25%
% of Gross Profit
Research & Development $3.255M $3.110M $12.51M
YoY Change 13.26% 11.07% -7.19%
% of Gross Profit
Depreciation & Amortization $50.00K $70.00K $290.0K
YoY Change -37.5% 0.0% 61.11%
% of Gross Profit
Operating Expenses $4.007M $6.593M $29.68M
YoY Change -39.17% 48.26% 9.46%
Operating Profit -$4.007M -$6.593M -$29.26M
YoY Change -34.97% 82.03% -1120.76%
Interest Expense $0.00 $0.00
YoY Change -100.0%
% of Operating Profit
Other Income/Expense, Net $44.00K $50.00K $226.0K
YoY Change -56.44% -106.1% -123.3%
Pretax Income -$3.960M -$6.550M -$29.03M
YoY Change -34.65% 85.55% -1631.07%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$3.963M -$6.547M -$29.03M
YoY Change -34.61% 85.41% -1635.11%
Net Earnings / Revenue
Basic Earnings Per Share -$1.11
Diluted Earnings Per Share -$111.0K -$215.2K -$1.11
COMMON SHARES
Basic Shares Outstanding 43.11M shares 31.83M shares 26.11M shares
Diluted Shares Outstanding 26.11M shares

Balance Sheet

Concept 2018 Q1 2017 Q4 2017
SHORT-TERM ASSETS
Cash & Short-Term Investments $19.70M $14.70M $14.70M
YoY Change -2.96% -41.9% -41.9%
Cash & Equivalents $19.69M $14.68M $14.70M
Short-Term Investments
Other Short-Term Assets $600.0K $300.0K $300.0K
YoY Change -14.29% -50.0% -50.0%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $20.33M $14.98M $15.00M
YoY Change -3.12% -42.22% -42.08%
LONG-TERM ASSETS
Property, Plant & Equipment $473.0K $522.0K $500.0K
YoY Change -33.75% -34.42% -37.5%
Goodwill $13.06M $13.06M
YoY Change -22.53% -22.53%
Intangibles $46.40M $46.40M
YoY Change -23.31% -23.31%
Long-Term Investments
YoY Change
Other Assets $19.00K $120.0K $100.0K
YoY Change
Total Long-Term Assets $59.97M $60.12M $60.10M
YoY Change -23.21% -23.1% -23.15%
TOTAL ASSETS
Total Short-Term Assets $20.33M $14.98M $15.00M
Total Long-Term Assets $59.97M $60.12M $60.10M
Total Assets $80.29M $75.10M $75.10M
YoY Change -18.95% -27.86% -27.86%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.393M $907.0K $900.0K
YoY Change 14.74% -45.59% -47.06%
Accrued Expenses $3.853M $3.813M $3.800M
YoY Change 103.11% 114.94% 137.5%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $5.246M $4.720M $4.700M
YoY Change 62.62% 18.59% 17.5%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $260.0K $215.0K $39.80M
YoY Change -99.44% -11.75%
Total Long-Term Liabilities $260.0K $215.0K $39.80M
YoY Change -99.44% -11.75%
TOTAL LIABILITIES
Total Short-Term Liabilities $5.246M $4.720M $4.700M
Total Long-Term Liabilities $260.0K $215.0K $39.80M
Total Liabilities $5.506M $4.935M $57.10M
YoY Change -91.68% 23.99% -12.69%
SHAREHOLDERS EQUITY
Retained Earnings -$156.3M -$152.3M
YoY Change 20.79% 23.53%
Common Stock $43.00K $35.00K
YoY Change 72.0% 40.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $23.86M $18.03M $18.00M
YoY Change
Total Liabilities & Shareholders Equity $80.29M $75.10M $75.10M
YoY Change -18.95% -27.86% -27.86%

Cashflow Statement

Concept 2018 Q1 2017 Q4 2017
OPERATING ACTIVITIES
Net Income -$3.963M -$6.547M -$29.03M
YoY Change -34.61% 85.41% -1635.11%
Depreciation, Depletion And Amortization $50.00K $70.00K $290.0K
YoY Change -37.5% 0.0% 61.11%
Cash From Operating Activities -$4.383M -$3.630M -$17.80M
YoY Change -15.63% -34.24% -801.34%
INVESTING ACTIVITIES
Capital Expenditures $10.00K
YoY Change
Acquisitions
YoY Change
Other Investing Activities $10.00K $20.00K $100.0K
YoY Change -87.5% -50.0% -78.26%
Cash From Investing Activities $5.000K $20.00K $98.00K
YoY Change -93.42% -50.0% -78.74%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $9.376M $0.00
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities $9.386M 6.960M $7.005M
YoY Change 20757.78% 6860.0% -150.69%
NET CHANGE
Cash From Operating Activities -$4.383M -3.630M -$17.80M
Cash From Investing Activities $5.000K 20.00K $98.00K
Cash From Financing Activities $9.386M 6.960M $7.005M
Net Change In Cash $5.008M 3.350M -$10.66M
YoY Change -198.7% -162.27% -1.47%
FREE CASH FLOW
Cash From Operating Activities -$4.383M -$3.630M -$17.80M
Capital Expenditures $10.00K
Free Cash Flow -$17.81M
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2017 dei Amendment Flag
AmendmentFlag
false
CY2017 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2017 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2017 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2017
CY2017 dei Document Period End Date
DocumentPeriodEndDate
2017-12-31
CY2017 dei Document Type
DocumentType
10-K
CY2017 dei Entity Central Index Key
EntityCentralIndexKey
0001485003
CY2018Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
43105466 shares
CY2017 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2017 dei Entity Filer Category
EntityFilerCategory
Smaller Reporting Company
CY2017Q2 dei Entity Public Float
EntityPublicFloat
24200000 USD
CY2017 dei Entity Registrant Name
EntityRegistrantName
Eleven Biotherapeutics, Inc.
CY2017 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2017 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2017 dei Trading Symbol
TradingSymbol
EBIO
CY2015 ebio Business Combination Changein Fair Valueof Contingent Consideration
BusinessCombinationChangeinFairValueofContingentConsideration
0 USD
CY2016 ebio Business Combination Changein Fair Valueof Contingent Consideration
BusinessCombinationChangeinFairValueofContingentConsideration
-1100000 USD
CY2017 ebio Business Combination Changein Fair Valueof Contingent Consideration
BusinessCombinationChangeinFairValueofContingentConsideration
9100000 USD
CY2017Q4 ebio Class Of Warrant Or Right Price Per Share
ClassOfWarrantOrRightPricePerShare
0.01
CY2016Q4 ebio Deferred Tax Assets Capitalized Start Up Costs
DeferredTaxAssetsCapitalizedStartUpCosts
246000 USD
CY2017Q4 ebio Deferred Tax Assets Capitalized Start Up Costs
DeferredTaxAssetsCapitalizedStartUpCosts
150000 USD
CY2016Q4 ebio Deferred Tax Assets Licenses
DeferredTaxAssetsLicenses
61000 USD
CY2017Q4 ebio Deferred Tax Assets Licenses
DeferredTaxAssetsLicenses
0 USD
CY2015 ebio Effective Income Tax Rate Reconciliation Contingent Consideration Percent
EffectiveIncomeTaxRateReconciliationContingentConsiderationPercent
0.000
CY2016 ebio Effective Income Tax Rate Reconciliation Contingent Consideration Percent
EffectiveIncomeTaxRateReconciliationContingentConsiderationPercent
0.157
CY2017 ebio Effective Income Tax Rate Reconciliation Contingent Consideration Percent
EffectiveIncomeTaxRateReconciliationContingentConsiderationPercent
0.107
CY2015 ebio Effective Income Tax Rate Reconciliation No Lwriteoff Percent
EffectiveIncomeTaxRateReconciliationNOLwriteoffPercent
0.000
CY2016 ebio Effective Income Tax Rate Reconciliation No Lwriteoff Percent
EffectiveIncomeTaxRateReconciliationNOLwriteoffPercent
0.144
CY2017 ebio Effective Income Tax Rate Reconciliation No Lwriteoff Percent
EffectiveIncomeTaxRateReconciliationNOLwriteoffPercent
0.000
CY2015 ebio Effective Income Tax Rate Reconciliation Permanent Differences
EffectiveIncomeTaxRateReconciliationPermanentDifferences
0.024
CY2016 ebio Effective Income Tax Rate Reconciliation Permanent Differences
EffectiveIncomeTaxRateReconciliationPermanentDifferences
0.053
CY2017 ebio Effective Income Tax Rate Reconciliation Permanent Differences
EffectiveIncomeTaxRateReconciliationPermanentDifferences
0.003
CY2015 ebio Effective Income Tax Rate Reconciliation Transaction Costs Percent
EffectiveIncomeTaxRateReconciliationTransactionCostsPercent
0.000
CY2016 ebio Effective Income Tax Rate Reconciliation Transaction Costs Percent
EffectiveIncomeTaxRateReconciliationTransactionCostsPercent
0.336
CY2017 ebio Effective Income Tax Rate Reconciliation Transaction Costs Percent
EffectiveIncomeTaxRateReconciliationTransactionCostsPercent
0.000
CY2015 ebio Issuance Of Warrant For Common Stock
IssuanceOfWarrantForCommonStock
328000 USD
CY2016 ebio Issuance Of Warrant For Common Stock
IssuanceOfWarrantForCommonStock
0 USD
CY2017 ebio Issuance Of Warrant For Common Stock
IssuanceOfWarrantForCommonStock
2679000 USD
CY2017 ebio Lessee Lease Agreement Notice Of Termination Period
LesseeLeaseAgreementNoticeOfTerminationPeriod
P30D
CY2016Q1 ebio License Agreement Termination Period
LicenseAgreementTerminationPeriod
P60D
CY2010Q3 ebio Number Of Common Stock Shares Issuable Upon Achievement Of Milestones
NumberOfCommonStockSharesIssuableUponAchievementOfMilestones
105000 shares
CY2017 ebio Numberof Geographic Segments
NumberofGeographicSegments
1 geographic_segment
CY2017Q4 ebio Operating Loss Carryforwards Decrease
OperatingLossCarryforwardsDecrease
800000 USD
CY2010Q3 ebio Potential Milestone Payments
PotentialMilestonePayments
4700000.0 USD
CY2013Q2 ebio Research Term
ResearchTerm
P30M
CY2016Q4 ebio Restricted Cash Fair Value Disclosure
RestrictedCashFairValueDisclosure
10000 USD
CY2017Q4 ebio Restricted Cash Fair Value Disclosure
RestrictedCashFairValueDisclosure
10000 USD
CY2016Q3 ebio Sharebased Compensation Arrangementby Sharebased Payment Award Additional Award Vesting Rights Percentage
SharebasedCompensationArrangementbySharebasedPaymentAwardAdditionalAwardVestingRightsPercentage
0.0625
CY2017 ebio Stock Issued During Period Exercise Of Warrants Value
StockIssuedDuringPeriodExerciseOfWarrantsValue
45000 USD
CY2017 ebio Tax Cuts And Jobs Act Of2017 Incomplete Accounting Change In Tax Rate Deferred Tax Asset Provisional Income Tax Expense
TaxCutsAndJobsActOf2017IncompleteAccountingChangeInTaxRateDeferredTaxAssetProvisionalIncomeTaxExpense
-14700000 USD
CY2017 ebio Tax Cuts And Jobs Act Of2017 Incomplete Accounting Change In Tax Rate Valuation Allowance Deferred Tax Asset Increase Decrease Amount
TaxCutsAndJobsActOf2017IncompleteAccountingChangeInTaxRateValuationAllowanceDeferredTaxAssetIncreaseDecreaseAmount
14700000 USD
CY2016Q4 ebio Warrant Liability
WarrantLiability
5000 USD
CY2017Q4 ebio Warrant Liability
WarrantLiability
0 USD
CY2017Q4 ebio Working Capital Net
WorkingCapitalNet
10300000 USD
CY2016Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1667000 USD
CY2017Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
907000 USD
CY2016Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1774000 USD
CY2017Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3813000 USD
CY2016Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
413000 USD
CY2017Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
463000 USD
CY2016Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
71000 USD
CY2017Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
331000 USD
CY2016Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
161963000 USD
CY2017Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
170330000 USD
CY2015 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2529000 USD
CY2016 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4013000 USD
CY2017 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1381000 USD
CY2015 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
819000 USD
CY2017 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
1000000 USD
CY2015 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
328000 USD
CY2016Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1700000 USD
CY2015 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2923003 shares
CY2016 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2326682 shares
CY2017 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
12755226 shares
CY2016Q4 us-gaap Assets
Assets
104097000 USD
CY2017Q4 us-gaap Assets
Assets
75097000 USD
CY2016Q4 us-gaap Assets Current
AssetsCurrent
25927000 USD
CY2017Q4 us-gaap Assets Current
AssetsCurrent
14981000 USD
CY2016Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
25352000 USD
CY2017Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
14690000 USD
CY2016 us-gaap Business Combination Acquisition Related Costs
BusinessCombinationAcquisitionRelatedCosts
2500000 USD
CY2016Q4 us-gaap Business Combination Contingent Consideration Liability Noncurrent
BusinessCombinationContingentConsiderationLiabilityNoncurrent
45100000 USD
CY2017Q4 us-gaap Business Combination Contingent Consideration Liability Noncurrent
BusinessCombinationContingentConsiderationLiabilityNoncurrent
39600000 USD
CY2015 us-gaap Business Combination Provisional Information Initial Accounting Incomplete Adjustment Consideration Transferred
BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentConsiderationTransferred
0 USD
CY2016 us-gaap Business Combination Provisional Information Initial Accounting Incomplete Adjustment Consideration Transferred
BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentConsiderationTransferred
0 USD
CY2017 us-gaap Business Combination Provisional Information Initial Accounting Incomplete Adjustment Consideration Transferred
BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentConsiderationTransferred
14600000 USD
CY2015 us-gaap Cash Acquired From Acquisition
CashAcquiredFromAcquisition
0 USD
CY2016 us-gaap Cash Acquired From Acquisition
CashAcquiredFromAcquisition
136000 USD
CY2017 us-gaap Cash Acquired From Acquisition
CashAcquiredFromAcquisition
0 USD
CY2014Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
54059000 USD
CY2015Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
36079000 USD
CY2016Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
25342000 USD
CY2017Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
14700000 USD
CY2017Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
14680000 USD
CY2016Q4 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
25342000 USD
CY2017Q4 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
14680000 USD
CY2015 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-17980000 USD
CY2016 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-10737000 USD
CY2017 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-10662000 USD
CY2016Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2017Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2016Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
4133703 shares
CY2017Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
13998426 shares
CY2016Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2017Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2016Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000 shares
CY2017Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000 shares
CY2016Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
24531964 shares
CY2017Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
34702565 shares
CY2016Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
24531964 shares
CY2017Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
34702565 shares
CY2016Q4 us-gaap Common Stock Value
CommonStockValue
25000 USD
CY2017Q4 us-gaap Common Stock Value
CommonStockValue
35000 USD
CY2016Q4 us-gaap Construction Payable Current
ConstructionPayableCurrent
852000 USD
CY2017Q4 us-gaap Construction Payable Current
ConstructionPayableCurrent
2581000 USD
CY2016Q4 us-gaap Cumulative Effect Of New Accounting Principle In Period Of Adoption
CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption
0 USD
CY2015 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
0 USD
CY2016 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
2000 USD
CY2017 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
0 USD
CY2015 us-gaap Current Foreign Tax Expense Benefit
CurrentForeignTaxExpenseBenefit
0 USD
CY2016 us-gaap Current Foreign Tax Expense Benefit
CurrentForeignTaxExpenseBenefit
0 USD
CY2017 us-gaap Current Foreign Tax Expense Benefit
CurrentForeignTaxExpenseBenefit
0 USD
CY2015 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
0 USD
CY2015 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
0 USD
CY2016 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
2000 USD
CY2017 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
0 USD
CY2015 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
0 USD
CY2016 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
0 USD
CY2017 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
0 USD
CY2016Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
51229000 USD
CY2016Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
425000 USD
CY2017Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
0 USD
CY2016 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
0 USD
CY2017 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
0 USD
CY2015 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
0 USD
CY2016 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
3000 USD
CY2017 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
0 USD
CY2015 us-gaap Deferred Foreign Income Tax Expense Benefit
DeferredForeignIncomeTaxExpenseBenefit
0 USD
CY2016 us-gaap Deferred Foreign Income Tax Expense Benefit
DeferredForeignIncomeTaxExpenseBenefit
0 USD
CY2017 us-gaap Deferred Foreign Income Tax Expense Benefit
DeferredForeignIncomeTaxExpenseBenefit
0 USD
CY2015 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
0 USD
CY2016 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
3000 USD
CY2017 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
0 USD
CY2016Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
16524000 USD
CY2017Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
12635000 USD
CY2017Q4 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
12528000 USD
CY2017Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
43211000 USD
CY2016Q4 us-gaap Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
3355000 USD
CY2017Q4 us-gaap Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
3690000 USD
CY2016Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
45488000 USD
CY2017Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
37070000 USD
CY2016Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
0 USD
CY2017Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
38000 USD
CY2016Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Other
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther
2079000 USD
CY2017Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Other
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther
2263000 USD
CY2016Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
51040000 USD
CY2016Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
51000000 USD
CY2017Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
43100000 USD
CY2017Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
43104000 USD
CY2016Q4 us-gaap Deferred Tax Liabilities
DeferredTaxLiabilities
16335000 USD
CY2017Q4 us-gaap Deferred Tax Liabilities
DeferredTaxLiabilities
12528000 USD
CY2016Q4 us-gaap Deferred Tax Liabilities Deferred Expense Capitalized Research And Development Costs
DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts
16335000 USD
CY2017Q4 us-gaap Deferred Tax Liabilities Deferred Expense Capitalized Research And Development Costs
DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts
12528000 USD
CY2016Q4 us-gaap Deferred Tax Liabilities Noncurrent
DeferredTaxLiabilitiesNoncurrent
16335000 USD
CY2016Q4 us-gaap Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
189000 USD
CY2017Q4 us-gaap Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
107000 USD
CY2015 us-gaap Depreciation And Amortization
DepreciationAndAmortization
366000 USD
CY2016 us-gaap Depreciation And Amortization
DepreciationAndAmortization
178000 USD
CY2017 us-gaap Depreciation And Amortization
DepreciationAndAmortization
285000 USD
CY2016Q4 us-gaap Derivative Fair Value Of Derivative Liability
DerivativeFairValueOfDerivativeLiability
5000 USD
CY2016Q4 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
114000 USD
CY2015 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.000
CY2017Q4 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
0 USD
CY2015 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.76
CY2016Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.39
CY2016Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.33
CY2016Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.95
CY2016Q4 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.15
CY2016 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.09
CY2017 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.11
CY2017Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.25
CY2017Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.30
CY2017Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.37
CY2017Q4 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.22
CY2017 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.11
CY2015 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.76
CY2016Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.39
CY2016Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.33
CY2016Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.91
CY2016Q4 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.15
CY2016 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.09
CY2017 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.11
CY2016 us-gaap Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
0.000
CY2017 us-gaap Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
-0.506
CY2015 us-gaap Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential
EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
0.000
CY2016 us-gaap Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential
EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
0.077
CY2017 us-gaap Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential
EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
-0.026
CY2015 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
0.000
CY2016 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
0.496
CY2017 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
-0.008
CY2015 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.056
CY2016 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.188
CY2016 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.003
CY2017 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.000
CY2015 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.3400
CY2016 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.3400
CY2017 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.34
CY2015 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
0.438
CY2016 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
1.224
CY2017 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.282
CY2015 us-gaap Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
0.000
CY2017 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.014
CY2015 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Other
EffectiveIncomeTaxRateReconciliationTaxCreditsOther
-0.018
CY2016 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Other
EffectiveIncomeTaxRateReconciliationTaxCreditsOther
0.250
CY2017 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Other
EffectiveIncomeTaxRateReconciliationTaxCreditsOther
-0.008
CY2016Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
352000 USD
CY2017Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
735000 USD
CY2017 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y4M28D
CY2017Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
1100000 USD
CY2015 us-gaap Employee Service Share Based Compensation Tax Benefit From Compensation Expense
EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
0 USD
CY2016 us-gaap Employee Service Share Based Compensation Tax Benefit From Compensation Expense
EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
0 USD
CY2017 us-gaap Employee Service Share Based Compensation Tax Benefit From Compensation Expense
EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
0 USD
CY2015 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-3104000 USD
CY2016 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-110000 USD
CY2017 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-5000 USD
CY2015 us-gaap Fair Value Of Assets Acquired
FairValueOfAssetsAcquired
0 USD
CY2016 us-gaap Fair Value Of Assets Acquired
FairValueOfAssetsAcquired
79366000 USD
CY2017 us-gaap Fair Value Of Assets Acquired
FairValueOfAssetsAcquired
0 USD
CY2015 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
0 USD
CY2016 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
24000 USD
CY2017 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
108000 USD
CY2015 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0 USD
CY2016 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-221000 USD
CY2017 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0 USD
CY2015 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
9850000 USD
CY2016 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
14736000 USD
CY2017 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8070000 USD
CY2016Q4 us-gaap Goodwill
Goodwill
16864000 USD
CY2017Q4 us-gaap Goodwill
Goodwill
13064000 USD
CY2017 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0 USD
CY2015 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-33452000 USD
CY2016 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
1896000 USD
CY2017 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-29029000 USD
CY2015 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-33452000 USD
CY2016 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
1896000 USD
CY2017 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-29029000 USD
CY2015 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
CY2016 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
5000 USD
CY2017 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
CY2015 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1212000 USD
CY2016 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-742000 USD
CY2017 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-760000 USD
CY2015 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
226000 USD
CY2016 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-1936000 USD
CY2017 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
1746000 USD
CY2015 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-100000 USD
CY2016 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
19000 USD
CY2017 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-425000 USD
CY2015 us-gaap Increase Decrease In Due To Related Parties
IncreaseDecreaseInDueToRelatedParties
0 USD
CY2016 us-gaap Increase Decrease In Due To Related Parties
IncreaseDecreaseInDueToRelatedParties
-698000 USD
CY2017 us-gaap Increase Decrease In Due To Related Parties
IncreaseDecreaseInDueToRelatedParties
-114000 USD
CY2015 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-110000 USD
CY2016 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-800000 USD
CY2017 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-164000 USD
CY2015 us-gaap Increase Decrease In Restricted Cash For Operating Activities
IncreaseDecreaseInRestrictedCashForOperatingActivities
0 USD
CY2016 us-gaap Increase Decrease In Restricted Cash For Operating Activities
IncreaseDecreaseInRestrictedCashForOperatingActivities
-84000 USD
CY2017 us-gaap Increase Decrease In Restricted Cash For Operating Activities
IncreaseDecreaseInRestrictedCashForOperatingActivities
0 USD
CY2016Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
60500000 USD
CY2017Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
46400000 USD
CY2015 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-1395000 USD
CY2016 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-247000 USD
CY2017 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
0 USD
CY2015 us-gaap Interest Paid
InterestPaid
930000 USD
CY2016 us-gaap Interest Paid
InterestPaid
663000 USD
CY2017 us-gaap Interest Paid
InterestPaid
0 USD
CY2016Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
104097000 USD
CY2017Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
75097000 USD
CY2015 us-gaap Liabilities Assumed1
LiabilitiesAssumed1
0 USD
CY2016 us-gaap Liabilities Assumed1
LiabilitiesAssumed1
19777000 USD
CY2017 us-gaap Liabilities Assumed1
LiabilitiesAssumed1
0 USD
CY2016Q4 us-gaap Liabilities Current
LiabilitiesCurrent
3980000 USD
CY2017Q4 us-gaap Liabilities Current
LiabilitiesCurrent
4720000 USD
CY2016Q4 us-gaap Liabilities Fair Value Disclosure
LiabilitiesFairValueDisclosure
45105000 USD
CY2017Q4 us-gaap Liabilities Fair Value Disclosure
LiabilitiesFairValueDisclosure
39600000 USD
CY2015 us-gaap Licenses Revenue
LicensesRevenue
500000 USD
CY2016 us-gaap Licenses Revenue
LicensesRevenue
29575000 USD
CY2017 us-gaap Licenses Revenue
LicensesRevenue
425000 USD
CY2015 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
16836000 USD
CY2016 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-13820000 USD
CY2017 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
7005000 USD
CY2015 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-287000 USD
CY2016 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
461000 USD
CY2017 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
98000 USD
CY2015 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-34529000 USD
CY2016 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-723000 USD
CY2017 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
226000 USD
CY2016Q4 us-gaap Net Income Loss
NetIncomeLoss
-3531000 USD
CY2016 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
2622000 USD
CY2017 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-17765000 USD
CY2015 us-gaap Net Income Loss
NetIncomeLoss
-33452000 USD
CY2016Q1 us-gaap Operating Expenses
OperatingExpenses
6779000 USD
CY2017 us-gaap Net Income Loss
NetIncomeLoss
-29029000 USD
CY2016Q1 us-gaap Net Income Loss
NetIncomeLoss
-7574000 USD
CY2016Q2 us-gaap Net Income Loss
NetIncomeLoss
-6491000 USD
CY2016Q3 us-gaap Net Income Loss
NetIncomeLoss
19487000 USD
CY2015 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1744000 USD
CY2016 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-970000 USD
CY2017Q1 us-gaap Net Income Loss
NetIncomeLoss
-6061000 USD
CY2017Q2 us-gaap Net Income Loss
NetIncomeLoss
-7316000 USD
CY2017Q3 us-gaap Net Income Loss
NetIncomeLoss
-9105000 USD
CY2017Q4 us-gaap Net Income Loss
NetIncomeLoss
-6547000 USD
CY2017 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
226000 USD
CY2017 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1 operating_segment
CY2015 us-gaap Operating Expenses
OperatingExpenses
36186000 USD
CY2016 us-gaap Net Income Loss
NetIncomeLoss
1891000 USD
CY2016Q2 us-gaap Operating Expenses
OperatingExpenses
6769000 USD
CY2016Q3 us-gaap Operating Expenses
OperatingExpenses
9120000 USD
CY2016Q4 us-gaap Operating Expenses
OperatingExpenses
4447000 USD
CY2016 us-gaap Operating Expenses
OperatingExpenses
27115000 USD
CY2017Q1 us-gaap Operating Expenses
OperatingExpenses
6587000 USD
CY2017Q2 us-gaap Operating Expenses
OperatingExpenses
7350000 USD
CY2017Q3 us-gaap Operating Expenses
OperatingExpenses
9150000 USD
CY2017Q4 us-gaap Operating Expenses
OperatingExpenses
6593000 USD
CY2017 us-gaap Operating Expenses
OperatingExpenses
29680000 USD
CY2015 us-gaap Operating Income Loss
OperatingIncomeLoss
-35196000 USD
CY2016Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-6550000 USD
CY2016Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-6492000 USD
CY2016Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
19530000 USD
CY2016Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
-3622000 USD
CY2016 us-gaap Operating Income Loss
OperatingIncomeLoss
2866000 USD
CY2017Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-6162000 USD
CY2017Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-7350000 USD
CY2017Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-9150000 USD
CY2017Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
-6593000 USD
CY2017 us-gaap Operating Income Loss
OperatingIncomeLoss
-29255000 USD
CY2017Q4 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
1016806000 USD
CY2017Q4 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
428806000 USD
CY2017Q4 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
252000000 USD
CY2017Q4 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
336000000 USD
CY2015 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
494000 USD
CY2016 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
565000 USD
CY2016Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
157000 USD
CY2017Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
34000 USD
CY2016Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
0 USD
CY2017Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
120000 USD
CY2016Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
0 USD
CY2017Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
215000 USD
CY2015 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
3139000 USD
CY2015 us-gaap Payments For Proceeds From Productive Assets
PaymentsForProceedsFromProductiveAssets
287000 USD
CY2015 us-gaap Paid In Kind Interest
PaidInKindInterest
108000 USD
CY2016 us-gaap Paid In Kind Interest
PaidInKindInterest
26000 USD
CY2017 us-gaap Paid In Kind Interest
PaidInKindInterest
0 USD
CY2017 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P7Y6M22D
CY2016 us-gaap Payments For Proceeds From Productive Assets
PaymentsForProceedsFromProductiveAssets
-325000 USD
CY2017 us-gaap Payments For Proceeds From Productive Assets
PaymentsForProceedsFromProductiveAssets
-98000 USD
CY2017 us-gaap Payments For Restructuring
PaymentsForRestructuring
90000 USD
CY2016Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2017Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2016Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2017Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2016Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2017Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2016Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2017Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2016Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2017Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2016Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
585000 USD
CY2017Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
301000 USD
CY2013Q2 us-gaap Proceeds From Collaborators
ProceedsFromCollaborators
1750000 USD
CY2015 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
12650000 USD
CY2016 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0 USD
CY2017 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
6908000 USD
CY2015 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
0 USD
CY2016 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
35000 USD
CY2017 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
12000 USD
CY2015 us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
5000000 USD
CY2016 us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
0 USD
CY2017 us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
0 USD
CY2015 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
63000 USD
CY2016 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
269000 USD
CY2017 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
85000 USD
CY2016 us-gaap Property Plant And Equipment Disposals
PropertyPlantAndEquipmentDisposals
299000 USD
CY2017 us-gaap Property Plant And Equipment Disposals
PropertyPlantAndEquipmentDisposals
0 USD
CY2016Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
867000 USD
CY2017Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
853000 USD
CY2016Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
796000 USD
CY2017Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
522000 USD
CY2015 us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
877000 USD
CY2016 us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
14124000 USD
CY2017 us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
0 USD
CY2015 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
26336000 USD
CY2016 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
13479000 USD
CY2017 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
12510000 USD
CY2016Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
10000 USD
CY2017Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
10000 USD
CY2017Q4 us-gaap Restructuring And Related Cost Expected Cost1
RestructuringAndRelatedCostExpectedCost1
100000 USD
CY2016Q3 us-gaap Restructuring Charges
RestructuringCharges
1300000 USD
CY2017 us-gaap Restructuring Charges
RestructuringCharges
170000 USD
CY2016Q2 us-gaap Restructuring Costs
RestructuringCosts
600000 USD
CY2016Q4 us-gaap Restructuring Reserve
RestructuringReserve
31000 USD
CY2017Q4 us-gaap Restructuring Reserve
RestructuringReserve
111000 USD
CY2016Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-123311000 USD
CY2017Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-152331000 USD
CY2017Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-152300000 USD
CY2015 us-gaap Revenues
Revenues
500000 USD
CY2015 us-gaap Revenues
Revenues
490000 USD
CY2016 us-gaap Revenues
Revenues
406000 USD
CY2017 us-gaap Revenues
Revenues
0 USD
CY2017 us-gaap Revenues
Revenues
0 USD
CY2017Q4 us-gaap Sale Of Stock Consideration Received On Transaction
SaleOfStockConsiderationReceivedOnTransaction
7000000 USD
CY2017Q4 us-gaap Sale Of Stock Number Of Shares Issued In Transaction
SaleOfStockNumberOfSharesIssuedInTransaction
5525000 shares
CY2015 us-gaap Sales Revenue Net
SalesRevenueNet
990000 USD
CY2016Q1 us-gaap Sales Revenue Net
SalesRevenueNet
229000 USD
CY2016Q2 us-gaap Sales Revenue Net
SalesRevenueNet
277000 USD
CY2016Q3 us-gaap Sales Revenue Net
SalesRevenueNet
28650000 USD
CY2016Q4 us-gaap Sales Revenue Net
SalesRevenueNet
825000 USD
CY2016 us-gaap Sales Revenue Net
SalesRevenueNet
29981000 USD
CY2017Q1 us-gaap Sales Revenue Net
SalesRevenueNet
425000 USD
CY2017Q2 us-gaap Sales Revenue Net
SalesRevenueNet
0 USD
CY2017Q3 us-gaap Sales Revenue Net
SalesRevenueNet
0 USD
CY2017Q4 us-gaap Sales Revenue Net
SalesRevenueNet
0 USD
CY2017 us-gaap Sales Revenue Net
SalesRevenueNet
425000 USD
CY2015 us-gaap Share Based Compensation
ShareBasedCompensation
2529000 USD
CY2016 us-gaap Share Based Compensation
ShareBasedCompensation
4013000 USD
CY2017 us-gaap Share Based Compensation
ShareBasedCompensation
1381000 USD
CY2016Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1
ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
P4Y
CY2016Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Additional Shares Authorized
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
650000 shares
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
1267285 shares
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
4.35
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
768000 USD
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
942000 USD
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
258000 USD
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
491297 shares
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1303025 shares
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
841000 USD
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
146000 USD
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2024468 shares
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2695796 shares
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
4.41
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
3.16
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
146000 USD
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
2275796 shares
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
3.45
CY2017 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0.28
CY2017 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
5.10
CY2017 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
1.64
CY2016Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Award Vesting Rights Percentage
SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
0.25
CY2017Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
146000 USD
CY2016 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y8M23D
CY2017 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y6M18D
CY2017 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P8Y3M29D
CY2015 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
1800000 USD
CY2016 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
3700000 USD
CY2017 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
1100000 USD
CY2016Q3 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
3.37
CY2015 us-gaap Stock Issued1
StockIssued1
0 USD
CY2016 us-gaap Stock Issued1
StockIssued1
13525000 USD
CY2017 us-gaap Stock Issued1
StockIssued1
0 USD
CY2017 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
140400 shares
CY2016 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
35000 USD
CY2017 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
12000 USD
CY2015 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
12650000 USD
CY2017 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
6908000 USD
CY2015 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
63000 USD
CY2016 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
269000 USD
CY2017 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
40000 USD
CY2014Q4 us-gaap Stockholders Equity
StockholdersEquity
36826000 USD
CY2015Q4 us-gaap Stockholders Equity
StockholdersEquity
18944000 USD
CY2016Q4 us-gaap Stockholders Equity
StockholdersEquity
38677000 USD
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
18034000 USD
CY2016Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0 USD
CY2017Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0 USD
CY2017 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
7900000 USD
CY2015 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
0 shares
CY2016 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
650109 shares
CY2017 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
0 shares
CY2015 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
18993000 shares
CY2016 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
21733000 shares
CY2017 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
26105000 shares
CY2015 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
18993000 shares
CY2016 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
21083000 shares
CY2017 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
26105000 shares
CY2017 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Concentrations of Credit Risk and Off-Balance-Sheet Risk</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company has no significant off-balance-sheet risk, such as foreign exchange contracts, option contracts, or other foreign hedging arrangements. Financial instruments that potentially expose the Company to concentrations of credit risk primarily consist of cash and cash equivalents. The Company places its cash and cash equivalents in a custodian account in accredited financial institutions.</font></div></div>
CY2017 us-gaap Use Of Estimates
UseOfEstimates
<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Use of Estimates</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Management considers many factors in selecting appropriate financial accounting policies and controls, and in developing the estimates and assumptions that are used in the preparation of these consolidated financial statements. Management must apply significant judgment in this process. In addition, other factors may affect estimates, including: expected business and operational changes, sensitivity and volatility associated with the assumptions used in developing estimates, and whether historical trends are expected to be representative of future trends. The estimation process often may yield a range of potentially reasonable estimates of the ultimate future outcomes and management must select an amount that falls within that range of reasonable estimates. This process may result in actual results differing materially from those estimated amounts used in the preparation of the consolidated financial statements. Estimates are used in the following areas, among others: stock-based compensation expense, fair value of warrants to purchase common stock, revenue recognition, fair value of intangible assets and goodwill, income taxes including the valuation allowance for deferred tax assets, accrued expenses, contingent consideration and going concern considerations. Actual results could differ from those estimates under different assumptions or conditions. Changes in estimates are reflected in reported results in the period in which they become known.</font></div></div>

Files In Submission

Name View Source Status
0001485003-18-000034-index-headers.html Edgar Link pending
0001485003-18-000034-index.html Edgar Link pending
0001485003-18-000034.txt Edgar Link pending
0001485003-18-000034-xbrl.zip Edgar Link pending
decillisconsultingagr_image1.gif Edgar Link pending
ebio-123117x10k.htm Edgar Link pending
ebio-123117x211.htm Edgar Link pending
ebio-123117x231.htm Edgar Link pending
ebio-123117x311.htm Edgar Link pending
ebio-123117x312.htm Edgar Link pending
ebio-123117x321.htm Edgar Link pending
ebio-20171231.xml Edgar Link completed
ebio-20171231.xsd Edgar Link pending
ebio-20171231_cal.xml Edgar Link unprocessable
ebio-20171231_def.xml Edgar Link unprocessable
ebio-20171231_lab.xml Edgar Link unprocessable
ebio-20171231_pre.xml Edgar Link unprocessable
ebio-ex1022johnjmccabe1020.htm Edgar Link pending
ebio-ex1027decillisconsult.htm Edgar Link pending
figure5a02.jpg Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
pipelinejpeg21sep2017a04.jpg Edgar Link pending
proxinjectedtumorsa02.jpg Edgar Link pending
proxuninjectedtumorsa02.jpg Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R72.htm Edgar Link pending
R73.htm Edgar Link pending
R74.htm Edgar Link pending
R75.htm Edgar Link pending
R76.htm Edgar Link pending
R77.htm Edgar Link pending
R78.htm Edgar Link pending
R79.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
scchna02.jpg Edgar Link pending
Show.js Edgar Link pending
treatmentarmaa02.jpg Edgar Link pending
treatmentarmba02.jpg Edgar Link pending
vb6845da02.jpg Edgar Link pending
vb6845preclinicaldataa02.jpg Edgar Link pending